Molecular tumor boards promoted
Precision Clinical Medicine highlighted the growing use of molecular tumor boards that integrate genomic profiling into multidisciplinary care for metastatic cancer. The promotion emphasized coordinated interpretation and clinical decision-making across specialties. (x.com)
Cancer care is increasingly relying on molecular tumor boards, where oncologists, pathologists, geneticists and other specialists review a patient’s tumor DNA to choose treatment. (annalsofoncology.org) The DNA readout usually comes from comprehensive genomic profiling, a broad sequencing test that scans hundreds of cancer-related genes for mutations, fusions and other changes that drugs may target. In a 2025 Belgian study of 872 patients at 12 hospitals, a 523-gene panel succeeded in 93% of cases and found actionable markers in 81%. (nature.com) A molecular tumor board then puts that lab report next to the biopsy, scans, prior treatments and the patient’s overall condition. A 2025 meta-analysis of 34 studies covering 12,176 patients said 20.8% received board-recommended therapy, with better overall survival and progression-free survival reported in comparative studies. (pmc.ncbi.nlm.nih.gov) This model has spread as cancer drugs are approved for smaller genetic subgroups instead of broad tumor types alone. The European Society for Medical Oncology published recommendations in 2025 on how these boards should be structured and run as genomic testing becomes more common in routine care. (annalsofoncology.org) The shift is most visible in metastatic and other advanced cancers, where standard options may be exhausted and a rare mutation can open a path to a targeted drug or clinical trial. Medicare has covered certain next-generation sequencing tests for patients with recurrent, relapsed, refractory, metastatic, or stage three or four cancer since a national decision issued on March 16, 2018. (cms.gov) Hospitals are also using virtual molecular tumor boards to bring in outside expertise when a local center lacks a specialist in a rare alteration. A 2024 review in The Oncologist said virtual boards can widen access to experts, datasets and trial-matching across institutions and countries. (academic.oup.com) The promise comes with limits. In the Belgian BALLETT study, the national board recommended treatment for 69% of patients, but 23% ultimately received a matched therapy, showing how drug access, trial availability, timing and a patient’s condition can narrow the path from sequencing result to treatment. (nature.com) Researchers and medical societies are now pushing to standardize who sits on these boards, which cases get reviewed, and how outcomes are measured. The goal is less about generating more DNA data than making sure the data changes a real treatment decision for a patient with advanced cancer. (annalsofoncology.org)
